杨文卓 主任医师，教授
硕士招生类型：学术型；专业型
硕士招生专业：内科学（消化内科学）
博士招生类型：学术型；专业型
博士招生专业：内科学（消化内科学）
所在院系：附属同济医院
联系方式：yangwenzhuo2002@163.com
课题组链接：
研究方向
主要任职
科研业绩

科研方向：慢性肝脏疾病的基础和临床研究（Research work: Basic and clinical research of chronic liver diseases）
临床特长：胃肠道及肝胰疾病诊治；超声内镜诊治(Clinical work: gastrointestinal and liver diseases; Endoscopic ultrasonography )
同济大学医学院副院长、同济临床医学院副院长；
中华医学会肝病分会脂肪肝及酒精性肝病学组委员、上海市医学会肝病分会委员、脂肪肝学组委员；
教育部临床医学专业认证专家；
中国医师协会毕业后教育委员会医学模拟教育分委会委员；
中国医师协会智能医学分委会常务委员；
上海市医学会医学教育分会委员
Deputy Dean of Tongji University, School of Medicine; Deputy Dean of Tongji Clinical Medical School.
Member of the Fatty Liver and Alcoholic Liver Diseases Group of the Chinese Medical Association Liver Diseases Branch;
Member of Liver Disease Branch of Shanghai Medical Association;Member of Fatty Liver disease Group
Expert for Clinical MedicinePprofessional Certification of Ministry of Education
Member of the Subcommittee of Medical Simulation Education of the Education Committee of the Chinese Medical Doctor Association
Standing Committee Member of the Intelligent Medicine Subcommittee of the Chinese Medical Doctor Association
Member of the Medical Education Branch of Shanghai Medical Association
近年科研主攻方向是慢性肝病基础及临床研究，致力于脂肪肝及肝纤维化发生机制及临床诊断治疗的研究。主持国家自然科学基金项目2项（在研1项）、上海市科委自然基金项目1项、中国肝炎防治基金会王宝恩肝纤维化研究基金1项、上海市卫生局项目2项（在研1项）；发表SCI及国内统计源期刊论文20余篇，参编著作6部；主持教改课题4项，获上海市教学成果奖2项、同济大学教学成果奖5项。
Research work is focused on clinical and basic research of fatty liver disease and liver fibrosis supported by projects from National Natural Science Foundation of China.(2 projects)、Shanghai Science and Technology Commission、Shanghai Health and Family Planning Commission、China Hepatitis Prevention and Control Foundation Wang Baoen Liver Fibrosis Research Fund etc. More than 30 papers were published.
一、科研项目(Reacher Projects)：1.国家自然科学基金项目：EGR1/miR-212/FGF-21通路在运动防治非酒精性脂肪性肝病中的作用（2019-2022年，主持）
National Natural Science Foundation of China: Role of EGR1/miR-212/FGF-21 pathway in exercise prevention and treatment of nonalcoholic fatty liver disease (2019-2022, Project leader)
2. 上海市卫生局科研项目（项目号**） 磷脂酶D对非酒精性脂肪肝防治作用的研究 （2017-2019年，主持）
Shanghai Municipal Health Bureau Research Project (Project No. **) Study on the role of phospholipase D in the prevention and treatment of nonalcoholic fatty liver (2017-2019, Project leader)
3.国家自然基金项目（No**）磷脂酶D对肝纤维化时肝星状细胞表型转换的调控及机制研究（2012-2015年，主持）
National Natural Science Foundation of China (Project No.**) ：Regulation and Mechanism of Phospholipase D on Hepatic Stellate Phenotype Transformation in Liver Fibrosis (2012-2015, Project leader)
4.上海市科委自然基金项目（项目号11ZR**）磷脂酶D对肝星状细胞表型转换的调控作用（2011-2014年，主持）
Shanghai Science and Technology Commission Natural Fund Project (Project No. 11ZR**): The regulation of phospholipase D on the phenotypic transformation of hepatic stellate cells by (2011-2014, Project leader)
5.上海市卫生局科研项目（项目号**） 磷脂酶D抑制剂抗肝纤维化形成的作用及机制研究（2010-2012年，主持）
Shanghai Municipal Health Bureau Research Project (Project No. **) :Study on the role and mechanism of phospholipase D inhibitors in the formation of liver fibrosis (2010-2012, Project leader)
6. 中国肝炎防治基金会王宝恩肝纤维化研究基金 磷脂酶D对肝星状细胞表型转换的调控作用（2011-2012年，主持）
China Hepatitis Prevention and Control Foundation Wang Baoen Liver Fibrosis Research Fund：Phospholipase D regulates the phenotypic transformation of hepatic stellate cells (2011-2012,Project leader)
二、近三年发表SCI论文（第一或通讯作者）：SCI papers published in the last three years (first or corresponding author)
1. Junjie Xiao, Yihua Bei，Jingqi Liu，Jasmina Dimitrova-Shumkovska，Dapeng Kuang，Qiulian Zhou，Jin Li，Yanning Yang，YangXiang，Fei Wang，Changqing Yang，Wenzhuo Yang(*). miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21，J. Cell. Mol. Med，2016,20(2)：204-216. (corresponding author)（IF：4.938）
2. Yang W(#), Yang Y, Xia L, Yang Y, Wang F, Song M, Chen X, Liu J, Song Y, Zhao Y, Yang C. MiR-221 Promotes Capan-2 Pancreatic Ductal Adenocarcinoma Cells Proliferation by Targeting PTEN-Akt. Cell Physiol Biochem. 2016 ,38(6):2366- 2374.（First author）(IF:5.104)
3. Liu J, Cao Y,Song Y,Huang Q,Wang F, Yang W(*)，Yang C(*). Telocytes in liver. Curr Stem Cell Res The. 2016;11(5):415-9.. (IF 2.645）(Co-corresponding author)
4. Xiao J, Lv D, Zhao Y, Chen X, Song M, Liu J, Bei Y, Wang F, Yang W(*), Yang C(*). miR-149 controls non-alcoholic fatty liver by targeting FGF -21. J Cell Mol Med. 2016 Apr 6. doi: 10.1111/jcmm.12848. [Epub ahead of print]. (Co-corresponding author)（IF：4.938）
5.Zhu, Xinyan ，Liu, Ruilin ，Kuang, Dapeng，Liu, Jingqi，Shi,Xiaomeng，Zhang, Tingting，Zeng, Yu，Sun, Xianghua，Zhang, Yi，Yang,Wenzhuo(*). The Role of Phospholipase D1 in Liver Fibrosis Induced by Dimethylnitrosamine In Vivo. Digestive Diseases and Sciences，2014，59（8）：1779-1788。（Corresponding author）（IF：2.613）